Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro.

× No keyword cloud information.

29 in total

Review 1. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors: Jeffrey I Weitz; John W Eikelboom; Meyer Michel Samama
Journal: Chest Date: 2012-02 Impact factor: 9.410

2. New and emerging anticoagulant therapies for venous thromboembolism.

Authors: Lori-Ann Linkins; Jeffrey I Weitz
Journal: Curr Treat Options Cardiovasc Med Date: 2010-04

3. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor.

Authors: Richard C Becker; Hongqiu Yang; Yuchen Barrett; Puneet Mohan; Jessie Wang; Lars Wallentin; John H Alexander
Journal: J Thromb Thrombolysis Date: 2011-08 Impact factor: 2.300

4. Direct oral anticoagulants (DOACs) and neck of femur fractures: Standardising the perioperative management and time to surgery.

Authors: Rohi Shah; Nomaan Sheikh; Jitendra Mangwani; Nicolette Morgan; Hamidreza Khairandish
Journal: J Clin Orthop Trauma Date: 2020-08-23

Review 5. Oral anticoagulants for Asian patients with atrial fibrillation.

Authors: Ian Sabir; Kaivan Khavandi; Jack Brownrigg; A John Camm
Journal: Nat Rev Cardiol Date: 2014-03-11 Impact factor: 32.419

Review 6. Apixaban in patients with Atrial Fibrillation: A Systematic Review.

Authors: Abhishek Maan; E Kevin Heist; Amir Y Shaikh; Jeremy N Ruskin; Moussa Mansour
Journal: J Atr Fibrillation Date: 2012-08-20

Review 7. Reversal of novel oral anticoagulants in patients with major bleeding.

Authors: Deborah M Siegal; Adam Cuker
Journal: J Thromb Thrombolysis Date: 2013-04 Impact factor: 2.300

8. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.

Authors: Charles Frost; Sunil Nepal; Jessie Wang; Alan Schuster; Wonkyung Byon; Rebecca A Boyd; Zhigang Yu; Andrew Shenker; Yu Chen Barrett; Rogelio Mosqueda-Garcia; Frank Lacreta
Journal: Br J Clin Pharmacol Date: 2013-11 Impact factor: 4.335

Review 9. Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Authors: Gillian M Keating
Journal: Drugs Date: 2013-06 Impact factor: 9.546

10. Apixaban: an emerging oral factor Xa inhibitor.

Authors: Christopher Roser-Jones; Richard C Becker
Journal: J Thromb Thrombolysis Date: 2010-01 Impact factor: 2.300